Mylan Accuses Warner, Mayne Of Plot To Delay Generics

Law360, New York (July 09, 2012, 4:50 PM ET) -- Mylan Pharmaceuticals Inc. on Friday accused Warner Chilcott PLC and Mayne Pharma Group Ltd. of conspiring to prevent and delay generic competition to its anti-acne and bacterial infection drug Doryx by making minor changes to the drug every few years, with no real benefit.

Mylan claims that since as early as 2005, Warner Chilcott and Mayne have unlawfully interfered with the regulatory process, causing delays in the approval of generic versions of Doryx and disrupting the market for the generic drug, violating the Sherman Act by...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers